News Commentary | July 22, 2021
Inbiose received this funding in the form of a loan from the European Investment Bank (EIB), helping the company scale up production for other new HMOs beyond 2’‑fucosyllactose. In line with its commercialization plans, Inbiose recently submitted applications for FDA's regulatory approval covering ... Not part of subscription
News Commentary | November 11, 2021
The expansion follows $350 million Series C funding in July and will see the company construct a 200,000 ft2 facility in Chicago — adding 200 staff to its workforce for a total of 350 by 2023. Its recent launch of a cream cheese spread and sausage patties distinguishes it from most alternative ... Not part of subscription
News Commentary | November 11, 2021
ADM has been keen on growing its gut health offerings, starting with the acquisition of Protexin in 2018. Over the past couple of years, the company has also expanded its existing product categories to accommodate new application areas. While the financial details of Deerland's acquisition are not ... To read more, click here.
by Harini Venkataraman
This funding round was co-led by Greenleaf Foods, S2G Ventures, SPC, and Evolution VC Partners, with participation from some of its previous investors, including Kellogg's CVC arm, bringing its total funding raised to date to $120 million. MycoTechnology will focus on expanding its mycelium platform for functional ingredients. While the company has previously commercialized flavor modulator and protein ingredients, this will be its first product development related to functional ingredients. It is looking to launch a powdered form of medicinal mushroom Cordyceps sinensis as a B2B ingredient. Clients interested in the functional ingredients space should engage to evaluate the downstream application compatibility of these ingredients.
For the original news article, click here .